Lazertinib Plus Amivantamab: FDA Nod Marks South Korea's First Homegrown Cancer Drug Milestone

What Is Lazertinib and Why Does This FDA Approval Matter?

Lazertinib is an oral, central-nervous-system-penetrant, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It selectively targets both common activating EGFR mutations — exon 19 deletions and L858R substitutions — as well as the T790M resistance mutation that frequently emerges after earlier-generation therapies. The drug was developed by South Korean pharmaceutical company Yuhan Corporation and licensed to Janssen (Johnson & Johnson) for global development outside Korea.

The approval is significant because lazertinib is widely recognized as the first anticancer drug domestically discovered and developed in South Korea to achieve U.S. Food and Drug Administration marketing authorization. For the Korean biopharmaceutical sector, which has historically focused on biosimilars and generics, this represents a structural shift toward original drug innovation and signals that the country's R&D ecosystem can produce therapies competitive in the world's most demanding regulatory market.

How Effective Is the Lazertinib-Amivantamab Combination Compared With Osimertinib?

The FDA decision was based on the MARIPOSA trial, a randomized Phase 3 study comparing the lazertinib-amivantamab combination against osimertinib — the current global standard of care — as first-line therapy in patients with locally advanced or metastatic EGFR-mutated NSCLC. The combination achieved a statistically significant improvement in progression-free survival, extending the time before disease worsened. Amivantamab, a bispecific antibody targeting both EGFR and the MET receptor, appears to complement lazertinib's intracellular kinase inhibition by blocking parallel resistance pathways.

The trade-off is toxicity. Because amivantamab is administered intravenously and has EGFR-directed immune effects, the combination is associated with higher rates of infusion reactions, rash, paronychia, venous thromboembolism, and other adverse events than oral osimertinib alone. Clinicians and patients now face a practical decision between a more intensive combination regimen with longer disease control and a simpler single-agent oral therapy — a choice that will likely be individualized based on disease burden, comorbidities, and patient preference.

What Does This Mean for Lung Cancer Patients and Korean Biopharma?

Lung cancer remains the leading cause of cancer death worldwide, and EGFR mutations are among the most common driver alterations — especially in patients of East Asian descent, where prevalence is substantially higher than in Western populations. Having an additional effective first-line regimen expands the menu of evidence-based options and is particularly relevant for the large affected patient pools in Asia. Subcutaneous formulations of amivantamab, approved more recently, may also reduce the time patients spend in infusion chairs.

For the Korean pharmaceutical industry, lazertinib's trajectory — from academic discovery through Yuhan's clinical development, global licensing, and ultimate FDA approval — is being cited as a proof-of-concept pathway for other domestic novel drug candidates. Industry observers expect it to catalyze additional venture investment, government R&D funding, and multinational licensing partnerships across Korean biotech, with oncology, immunology, and metabolic disease as the most active pipelines.